DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in...

yahoo.com     Jul 18, 2008            

EWING, NJ--(MARKET WIRE)--Jul 18, 2008 -- DOR BioPharma, Inc. (OTC BB:DORB.OB - News ) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Steward Cross Pte Ltd (Steward Cross), a specialty pharmaceutical company based in Singapore, under which Steward Cross will act as DOR's Sponsor with regard to the administration of a Named Patient Access Program (NPAP) for orBec® to patients suffering from acute gastrointestinal Graft-versus-Host disease (GI GVHD) in Singapore and Malaysia. The NPAP is a compassionate use drug supply program administered by the Health Sciences Authority (HSA) of... [read full story]                    


*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies